Pharmacogenomics in the era of next generation sequencing – from byte to bedside

Published on May 17, 2021in Drug Metabolism Reviews3.956
· DOI :10.1080/03602532.2021.1909613
Laura E Russell3
Estimated H-index: 3
,
Yitian Zhou10
Estimated H-index: 10
(KI: Karolinska Institutet)
+ 3 AuthorsVolker M. Lauschke30
Estimated H-index: 30
(KI: Karolinska Institutet)
Source
Abstract
Pharmacogenetic research has resulted in the identification of a multitude of genetic variants that impact drug response or toxicity. These polymorphisms are mostly common and have been included as actionable information in the labels of numerous drugs. In addition to common variants, recent advances in Next Generation Sequencing (NGS) technologies have resulted in the identification of a plethora of rare and population-specific pharmacogenetic variations with unclear functional consequences that are not accessible by conventional forward genetics strategies. In this review, we discuss how comprehensive sequencing information can be translated into personalized pharmacogenomic advice in the age of NGS. Specifically, we provide an update of the functional impacts of rare pharmacogenetic variability and how this information can be leveraged to improve pharmacogenetic guidance. Furthermore, we critically discuss the current status of implementation of pharmacogenetic testing across drug development and layers of care. We identify major gaps and provide perspectives on how these can be minimized to optimize the utilization of NGS data for personalized clinical decision-support.
Figures & Tables
Download
References205
Newest
#1Mirjam Kauppila (UH: University of Helsinki)H-Index: 1
#2Janne T. Backman (UH: University of Helsinki)H-Index: 77
Last. Outi Lapatto-Reiniluoto (UH: University of Helsinki)H-Index: 6
view all 4 authors...
To investigate the characteristics of ADRs in patients admitting at the emergency room of a tertiary hospital. We collected the patient records of 1600 emergency room visits of a university hospital in 2018. The patient files were studied retrospectively and all possible ADRs were identified and registered. Patient characteristics, drugs associated with ADRs, causality, severity, preventability, and the role of pharmacogenetics were assessed. There were 125 cases with ADRs, resulting in a 7.8% o...
3 CitationsSource
#1John Young (University of Mississippi)H-Index: 17
#2Kaustuv Bhattacharya (University of Mississippi)H-Index: 2
Last. John P. Bentley (University of Mississippi)H-Index: 14
view all 5 authors...
This study examined rates of genetic testing in two cohorts of publicly insured individuals who have newly prescribed medication with FDA pharmacogenomic labeling guidance. Genetic testing was rare (4.4% and 10.5% in Medicaid and Medicare cohorts, respectively) despite the fact that all participants selected were taking medications that contained pharmacogenomic labeling information. When testing was conducted it was typically done before the initial use of a target medication. Factors that emer...
1 CitationsSource
#1Koya FukunagaH-Index: 7
#2Eiji Hishinuma (Tohoku University)H-Index: 5
Last. Taisei MushirodaH-Index: 44
view all 11 authors...
Next-generation sequencing (NGS) has identified variations in cytochrome P450 (CYP) 2D6 associated with drug responses. However, determination of novel haplotypes is difficult because of the short reads generated by NGS. We aimed to identify novel CYP2D6 variants in the Japanese population and predict the CYP2D6 phenotype based on in vitro metabolic studies. Using a targeted NGS panel (PKSeq), 990 Japanese genomes were sequenced, and then novel CYP2D6 haplotypes were determined. Km, Vmax, and in...
4 CitationsSource
#1Laura E Russell (UWO: University of Western Ontario)H-Index: 3
#2Marianne K. DeGorter (UWO: University of Western Ontario)H-Index: 13
Last. Richard B. Kim (UWO: University of Western Ontario)H-Index: 97
view all 7 authors...
1 CitationsSource
#1Yitian Zhou (KI: Karolinska Institutet)H-Index: 10
#2Kristi Krebs (UT: University of Tartu)H-Index: 5
Last. Volker M. Lauschke (KI: Karolinska Institutet)H-Index: 30
view all 4 authors...
Immune-mediated drug hypersensitivity reactions are an important source of iatrogenic morbidity and mortality. HLA-B*57:01, HLA-B*15:02, HLA-A*31:01 and HLA-B*58:01 constitute established risk factors and preemptive genotyping of these HLA alleles in patients prior to the initiation of abacavir, carbamazepine and allopurinol-based therapies can prevent toxicity and improve patient outcomes. However, the cost-effectiveness of preemptive HLA testing has only been evaluated in the US and few countr...
11 CitationsSource
#1Brahim Achour (RMIT: RMIT University)H-Index: 19
#2Zubida M. Al-Majdoub (RMIT: RMIT University)H-Index: 7
Last. Amin Rostami-Hodjegan (Princeton University)H-Index: 72
view all 10 authors...
Variability in individual capacity for hepatic elimination of therapeutic drugs is well recognized and is associated with variable expression and activity of liver enzymes and transporters. Whilst genotyping offers some degree of stratification, there is often large variability within the same genotype. Direct measurement of protein expression is impractical due to limited access to tissue biopsies. Hence, determination of variability in hepatic drug metabolism and disposition using liquid biops...
16 CitationsSource
#1Bonnie M. Vest (SUNY: State University of New York System)H-Index: 10
#2Laura O. Wray (SUNY: State University of New York System)H-Index: 10
Last. David W. Oslin (UPenn: University of Pennsylvania)H-Index: 70
view all 8 authors...
Pharmacogenetic testing (PGx) has the potential to improve the quality of psychiatric prescribing by considering patients’ genetic profile. However, there is limited scientific evidence supporting its efficacy or guiding its implementation. The Precision Medicine in Mental Health (PRIME) Care study is a pragmatic randomized controlled trial evaluating the effectiveness of a specific commercially-available pharmacogenetic (PGx) test to inform antidepressant prescribing at 22 sites across the U.S....
6 CitationsSource
#1Roberto Viviani (University of Innsbruck)H-Index: 23
#2Irene Messina (University of Ulm)H-Index: 3
Last. Julia C. Stingl (RWTH Aachen University)H-Index: 30
view all 8 authors...
The polymorphic drug-metabolizing enzyme CYP2D6, which is responsible for the metabolism of most psychoactive compounds, is expressed not only in the liver, but also in the brain. The effects of its marked genetic polymorphism on the individual capacity to metabolize drugs are well known, but its role in metabolism of neural substrates affecting behavior personality or cognition, suggested by its CNS expression, is a long-standing unresolved issue. To verify earlier findings suggesting a potenti...
4 CitationsSource
#68Lili Milani (UT: University of Tartu)H-Index: 63
#69João Fadista (SSI: Statens Serum Institut)H-Index: 26
Summary Hypersensitivity reactions to drugs are often unpredictable and can be life threatening, underscoring a need for understanding their underlying mechanisms and risk factors. The extent to which germline genetic variation influences the risk of commonly reported drug allergies such as penicillin allergy remains largely unknown. We extracted data from the electronic health records of more than 600,000 participants from the UK, Estonian, and Vanderbilt University Medical Center’s BioVU bioba...
6 CitationsSource
#1Jasleen K. Sodhi (UCSF: University of California, San Francisco)H-Index: 9
#2Shuaibing Liu (Zhengzhou University)H-Index: 2
Last. Leslie Z. Benet (UCSF: University of California, San Francisco)H-Index: 102
view all 3 authors...
The involvement of the intestinally expressed xenobiotic transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in apixaban disposition based on in vitro studies. Recommendations against co-administration of apixaban with inhibitors of these efflux transporters can be found throughout the literature as well as in the apixaban FDA label. However, the clinical relevance of such findings is questionable due to the high permeability and high solubility ch...
4 CitationsSource
Cited By3
Newest
#1Antonio F. Pardiñas (Cardiff University)H-Index: 21
#2Michael John Owen (Cardiff University)H-Index: 180
Last. James T.R. Walters (Cardiff University)H-Index: 51
view all 3 authors...
Summary null null Psychiatric genomics is providing insights into the nature of psychiatric conditions that in time should identify new drug targets and improve patient care. Less attention has been paid to psychiatric pharmacogenomics research, despite its potential to deliver more rapid change in clinical practice and patient outcomes. The pharmacogenomics of treatment response encapsulates both pharmacokinetic (“what the body does to a drug”) and pharmacodynamic (“what the drug does to the bo...
Source
#1Aarzoo Thakur (Agency for Science, Technology and Research)H-Index: 2
Last. Chukwunonso K NwabufoH-Index: 1
view all 8 authors...
A reliable, rapid, and effective bioanalytical method is essential for the determination of the pharmacokinetic, pharmacodynamic, and toxicokinetic parameters that inform the safety and efficacy profile of investigational drugs. The overall goal of bioanalytical method development is to elucidate the procedure and operating conditions under which a method can sufficiently extract, qualify, and/or quantify the analyte(s) of interest and/or their metabolites for the intended purpose. Given the dif...
Source
#1Yitian Zhou (KI: Karolinska Institutet)H-Index: 10
#2Volker M. Lauschke (KI: Karolinska Institutet)H-Index: 30
Inter-individual differences in drug response are a common concern in both drug development and across layers of care. While genetics clearly influence drug response and toxicity of many drugs, a substantial fraction of the heritable pharmacological and toxicological variability remains unexplained by known genetic polymorphisms. In recent years, population-scale sequencing projects have unveiled tens of thousands of coding and non-coding pharmacogenetic variants with unclear functional effects ...
4 CitationsSource